Clinical trial · Observational
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
NCT05804331CI-TRIAL-00087758ANZ UGIrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Stomach | Malignant Gastric Neoplasm | ALIAS | 0.90 |
| Esophageal Neoplasms | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Gastric Adenocarcinoma | Gastric Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Gastric Neoplasm | Gastric Neoplasm | ONTOLOGY_EXACT | 0.98 |
| GI Cancer | — | UNRESOLVED | — |
| GIST | Gastrointestinal Stromal Tumor | ALIAS | 0.90 |
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
| Oesophageal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patient with Gastrointestinal neoplasm
- description
- Pt referred for resection of gastrointestinal neoplasm. Observational data collected from endoscopic submucosal dissection (ESD), submucosal-tunnelling endoscopic resection (STER) or endoscopic full-thickness resection (EFTR) of gastrointestinal neoplasm
Primary outcomes (3)
- measure
- Effectiveness of endoscopic resection of UGI neoplastic lesions: completeness of resection
- timeFrame
- 2 weeks
- description
- Determined based on clear margins in histology review
- measure
- Safety: intra and post procedural; bleeding; perforation; anaesthetic
- timeFrame
- 30 day
- description
- Intraprocedural bleeding, clinically significant post-polypectomy bleeding, deep mural injury, post polypectomy coagulation syndrome
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * UGI neoplastic lesions \> 10mm * Lesions for ESD limited to the mucosal and/or submucosal layer OR * Lesions for EFTR limited to the muscularis propria layer OR * Lesions for STER limited to the submucosal and/or muscularis propria layer * Aged 18 years or older Exclusion Criteria: * Age less than 18 * Unable to give informed consent * Pregnant or lactating patients * Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally
References
Publications (0)
Data not yet available
No reference posted for this study.